Navigation Links
Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
Date:11/19/2009

3,000 or approximately 1% of all children in the U.S.

For information on participating in the CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance o
'/>"/>

SOURCE Curemark LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
2. Curemark Announces Senior Executive Promotions
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Closes Series A Financing
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
7. Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
8. Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually
9. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
10. TCP Innovations Opens First US Office
11. New Places and People - Truphatek opens USA subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... leukemia is a malignant condition characterized by increased production ... first affects B-lymphocytes and then it can spread to ... mostly at later stages because of the slow buildup ... disease, the malignancy spreads to the spleen, liver, and ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... , SAN FRANCISCO , May 18 ... demonstrated patients treated with a standard or low dose of ... in how often they were awakened at night by hot ... presented today at the 58th Annual Clinical Meeting of the ...
... NANJING , China, May 18 /PRNewswire-Asia/ -- ... ), a leading pharmaceutical company,specializing in the development, manufacturing, and ... preliminary,unaudited financial results for the quarter ended March 31, ... -- Total revenue was RMB458.7 million (US$67.2 million) for ...
Cached Medicine Technology:New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 2Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 3Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 4Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 5Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 6Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 8Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 9Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 10Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 11Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 12
(Date:9/3/2015)... ... 03, 2015 , ... DiabetesSisters Welcomes Carol Wysham to Board ... of Carol Wysham, MD, to their esteemed Board of Directors. Dr. Wysham was ... Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson and Vicki Norris. As ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... ... 03, 2015 , ... The new In-Office whitening kit from ... The Clinicians Report is a leading information source to the dental industry. Product ... Whiter Image's In-Office whitening kits were favorably validated for use in the dental ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will be ... In this episode, James Earl Jones will introduce a segment that discusses why it ... and how workplace wellness can be fostered in any working environment. , Employers are ...
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located in ... towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda ... whole mind-body approach to fitness - we are much more than a gym. ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2
... , ... announces that their Electronic Health Record, Perfect Care EHR® ... Information Technology (CCHIT®) and is Preliminary ARRA 2011 certified, ... Use Objectives for Eligible Providers under the American Recovery ...
... drug cocktail might be the right mix to fight ... Details of a new study supporting this approach suggest ... work again. The findings were presented today at the ... involves post-menopausal women whose advanced breast cancers are fueled ...
... that could prevent another blood clot, study finds , ... stroke survivors don,t take medications that can reduce their risk ... stroke is caused by blocked blood flow in the brain. ... ischemic stroke. These include blood thinners (antithrombotic medications), of which ...
... , , , WINSTON-SALEM, N.C., Dec. 11 ... officers once again put the spotlight on mass murder in ... killings at Fort Hood, the Washington case raised questions about ... rampage. , Andrew Smiler, an assistant professor of psychology at ...
... , DALLAS, Dec. 11 For their ... rehabilitation for younger, more active cardiac patients, the Cardiac ... Heart and Vascular Hospital was recently awarded the Innovation ... Rehabilitation (AACVPR). The award acknowledges programs that have enhanced ...
... survey respondents were under 35 when they sought treatment , ... that age is an important factor in the success of ... 18 and older, including 125 women who,ve had fertility treatment. ... were under age 35 when they first sought medical advice ...
Cached Medicine News:Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 2Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 3Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Mass Murderers: Why Do They Kill? 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 3Health News:Women Aren't Waiting to Seek Infertility Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: